ConductScience.org, home

Paper39309477

Does Comorbid Food Allergy Affect Response to Omalizumab in Patients with Asthma?

Fiocchi A and 8 others. J Asthma Allergy, 2024. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Does Comorbid Food Allergy Affect Response to Omalizumab in Patients with Asthma? Papers, record 39309477. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39309477

Download JSON
Disease
asthma423 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Does Comorbid Food Allergy Affect Response to Omalizumab in Patients with Asthma?
PubMed
Journal
J Asthma Allergy
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.55, provisional
iCite
Revised in PubMed
2024-09-24
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fiocchi AAlessandro
2Chinthrajah RSR Sharonhttps://orcid.org/0000-0003-2467-4256
3Ansotegui IJIgnacio J
4Sriaroon PPanida
5Mustafa SSS Shahzad
6Raut PPranil
7Cameron BBriana
8Gupta SSachin
9Fleischer DMDavid M

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials3

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00079937Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic AsthmaDerived from the trialYesClinicalTrials.gov
NCT00252135A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe AsthmaDerived from the trialYesClinicalTrials.gov
NCT01922037A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)Derived from the trialYesClinicalTrials.gov

Download CSV of trials

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136119657Managing food allergy: GA2LEN guideline 2022.World Allergy Organ J2022https://conductscience.org/library/papers/36119657PubMed
238407394Omalizumab for the Treatment of Multiple Food Allergies.N Engl J Med2024https://conductscience.org/library/papers/38407394PubMed
333465457No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities.Ann Allergy Asthma Immunol2021https://conductscience.org/library/papers/33465457PubMed
411496232Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.J Allergy Clin Immunol2001https://conductscience.org/library/papers/11496232PubMed
530797778Impact of Omalizumab on Food Allergy in Patients Treated for Asthma: A Real-Life Study.J Allergy Clin Immunol Pract2019https://conductscience.org/library/papers/30797778PubMed
637779534Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH).J Allergy Clin Immunol Glob2022https://conductscience.org/library/papers/37779534PubMed
725923451Perceived food hypersensitivity relates to poor asthma control and quality of life in young non-atopic asthmatics.PLoS One2015https://conductscience.org/library/papers/25923451PubMed
818380635Assessing productivity loss and activity impairment in severe or difficult-to-treat asthma.Value Health2008https://conductscience.org/library/papers/18380635PubMed
911529281The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.Eur Respir J2001https://conductscience.org/library/papers/11529281PubMed
1019788018Baseline characteristics of patients enrolled in EXCELS: a cohort study.Ann Allergy Asthma Immunol2009https://conductscience.org/library/papers/19788018PubMed
1119910033Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.J Allergy Clin Immunol2009https://conductscience.org/library/papers/19910033PubMed
1217469157Food allergy and asthma morbidity in children.Pediatr Pulmonol2007https://conductscience.org/library/papers/17469157PubMed
1334588784Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study.J Asthma Allergy2021https://conductscience.org/library/papers/34588784PubMed
1411150011Fatalities due to anaphylactic reactions to foods.J Allergy Clin Immunol2001https://conductscience.org/library/papers/11150011PubMed
1526215729Pathogenesis of IgE-mediated food allergy.Clin Exp Allergy2015https://conductscience.org/library/papers/26215729PubMed
1635539896World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guideline update - XIV - Recommendations on CMA immunotherapy.World Allergy Organ J2022https://conductscience.org/library/papers/35539896PubMed
1714713908Development of the asthma control test: a survey for assessing asthma control.J Allergy Clin Immunol2004https://conductscience.org/library/papers/14713908PubMed
1836681581Might biologics serve to interrupt the atopic march?J Allergy Clin Immunol2023https://conductscience.org/library/papers/36681581PubMed
1924058900Food allergy and increased asthma morbidity in a School-based Inner-City Asthma Study.J Allergy Clin Immunol Pract2013https://conductscience.org/library/papers/24058900PubMed
201549827Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.Thorax1992https://conductscience.org/library/papers/1549827PubMed

See all 33 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
41208997Systematic review and meta-analysis of omalizumab for IgE-mediated food allergy in children and young adults.Front Immunol2025https://conductscience.org/library/papers/41208997PubMed
40497014Health care resource utilization of patients with asthma and food allergy initiating omalizumab.J Allergy Clin Immunol Glob2025https://conductscience.org/library/papers/40497014PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IGHE3497PubTator's text mininghttps://conductscience.org/library/genes/3497

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
OMALIZUMABCHEMBL1201589Derived from the trial2https://conductscience.org/library/drugs/CHEMBL1201589

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39309477

GET https://conductscience.org/api/papers/v1/39309477/references?page=2